SAR 445611
Alternative Names: Anti-CX3CR1 NANOBODY® VHH - Sanofi; SAR-445611Latest Information Update: 30 Nov 2023
At a glance
- Originator Sanofi
- Class Anti-inflammatories; Antibodies; Single-domain antibodies
- Mechanism of Action CX3C chemokine receptor 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation